US biotech firm Cytokinetics (Nasdaq: CYTK) and Japanese pharma major Astellas Pharma (TYO: 4503) have amended their collaboration agreement focused on the research, development and commercialization of skeletal muscle activators.
Shares of Cytokinetics jumped as much as 12.7% following the news on December 24, but closed the holiday-shortened trading day up 6.3% at $5.87.
The companies have been jointly conducting R&D activities with the objective to advance novel skeletal sarcomere targeted therapies for diseases and medical conditions associated with muscle weakness in non-neuromuscular indications. The collaboration has been expanded to enable development of CK-2127107, a fast skeletal troponin activator, in spinal muscular atrophy (SMA) and potentially other neuromuscular indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze